LY191704 inhibits type I steroid 5α-reductase in human scalp

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 6, 1996, Pages 2055-2060

  Neubauer, Blake Lee ^a   Gray, Howard M ^b   Hanke, C William ^b   Hirsch, Kenneth S ^a   Hsiao, Kenneth C ^a   Jones, C David ^a   Kumar, M Vijay ^c   Lawhorn, David E ^a   Lindzey, Jonathon ^c   Mcquaid, Loretta ^a   Tindall, Donald J ^c   Toomey, Richard E ^a   Yao, Raymond C ^a   Audia, James E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA (N,N DIETHYLCARBAMOYL) 4 METHYL 4 AZA 5ALPHA ANDROSTAN 3 ONE; 8 CHLORO 1,2,3,4,4A,5,6,10B OCTAHYDRO 4 METHYLBENZO[F]QUINOLIN 3(2H) ONE; EPRISTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE;

ARTICLE; COMPETITIVE INHIBITION; CORTICOSTEROID METABOLISM; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; MICHAELIS CONSTANT; MOLECULAR CLONING; PRIORITY JOURNAL; SCALP; UROGENITAL SINUS;

ANIMALS; BINDING, COMPETITIVE; DIHYDROTESTOSTERONE; HUMANS; ISOENZYMES; MALE; MICE; OSMOLAR CONCENTRATION; QUINOLONES; SCALP; TESTOSTERONE 5-ALPHA-REDUCTASE;

MURINAE; UNIDENTIFIED BACULOVIRUS;

EID: 9344244697     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.6.2055     Document Type: Article

References (39)

1. Bruchovsky N, Wilson JD 1968 The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem. 243:2012-2021.
2. Metcalf BW, Levy MA, Holt DA 1989 Inhibitors of steroid 5 alpha-reductase in benign prostatic hyperplasia, male pattern baldness and acne. Trends Pharmacol Sci. 10:491-495.
3. Andersson S, Bishop RW, Russell D W 1989 Expression cloning and regulation of steroid 5α-reductase, an enzyme essential for male sexual differentiation. J Biol Chem. 264:16249-16255.
4. Andersson S, Berman DM, Jenkins EP, Russell D W 1991 Deletion of steroid 5α-reductase 2 in male pseudohermaphroditism. Nature 354:159-161.
5. Bruchovsky N, Rennie PS, Batzold FH, Goldenberg SL, Fletcher T, McLoughlin MG 1988 Kinetic parameters of 5α-reductase activity in stroma and epithelium of normal, hyperplastic and carcinomatous human prostates. J Clin Endocrinol Metab. 67:806-816.
6. Moore RJ, Wilson JD. 1976 Steroid 5-alpha-reductase in cultured human fibroblasts. Biochemical and genetic evidence lor two distinct enzyme activities. J Biol Chem. 251:5895-5900.
7. Martini L, Zoppi S, Motta M. 1986 Studies on the possible existence of two 5 alpha-reductases in the rat prostate. J Steroid Biochem. 24:177-182.
8. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. 1993 Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 92:903-910.
9. Thigpen AE, Davis DL, Milatovich A, et al. 1992 Molecular genetics of steroid 5α-reductase 2 deficiency. J Clin Invest. 90:799-809.
10. Wilson JD, Griffin JE, Russell DW. 1993 Steroid 5α-reductase 2 deficiency. Endocr Rev. 14:577-593.
11. Normington K, Russell DW. 1992 Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. J Biol Chem 267:19548-19554.
12. Itami S, Kurata S, Takayasu S. 1990 5 alpha-reductase activity in cultured human dermal papilla cells from beard compared with reticular dermal fibroblasts. J Invest Dermatol. 94:150-152.
13. Itami S, Kurata S, Sonoda T, Takayasu S. 1991 Characterization of 5 alpha-reductase in cultured human dermal papilla cells from beard and occipital scalp hair. J Invest Dermatol. 96:57-60.
14. Harris G, Azzolina B, Baginsky W, et al. 1992 Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp. Proc Natl Acad Sci USA. 89:10787-10791.
15. Hirsch KS, Jones CD, Audia JE, et al. 1993 LY191704: a selective, non-steroidal inhibitor of human steroid 5α-reductase type 1. Proc Nat Acad Sci USA. 90:5277-5281.
16. Liang T, Cascieri MA, Cheung AH, Reynolds GF, Rasmusson GH. 1985 Species differences in prostatic steroid 5α-reductases of rat, dog and human. Endocrinology. 117:571-579.
17. Bradford, MM. 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248-254.
18. Sall J, Ng K, Hecht M. 1989 Regression and curve fitting. JMP Version 2 User's Guide. Cary, NC: SAS Institute; 243-262.
19. Toomey RE, Goode RL, Petrow V, Neubauer BL. 1991 An in vivo assay for conversion of testosterone to dihydrotestosterone by rat prostatic steroid 5 alpha-reductase and comparison of two inhibitors. Prostate. 19:63-72.
20. Lucknow VA, Summer MD. 1989 High level expression of non-fused genes with Autogtaphica californica nuclear polyhedrosis virus expression vectors. Virology. 170:31-39.
21. Webb NR, Summers MD. 1990 Expression of proteins using recombinant baculoviruses. Technique 2:173-188.
22. He WW, Fischer LM, Sun S, et al. 1990 Molecular cloning of androgen receptors from different species with a polymerase chain reaction technique: complete cDNA sequence of the mouse androgen receptor and isolation of cDNA probes from dog, guinea pig and clawed frog. Biochem Biophys Res Commun. 171:697-704.
23. Summers MD, Smith GE. 1987 A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures. College Station, TX: Texas Agricultural Experimental Station Bulletin, 1555.
24. Rasmusson GH, Reynolds GF, Steinberg NG, et al. 1986 Azasteroids: structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding. J Med Chem. 29:2298-2315.
25. Holt DA, Levy MA, Oh H-Y, et al. 1990 Inhibition of steroid 5 alpha-reductase by unsaturated 3-carboxysteroids. J Med Chem. 33:943-950.
26. Segal IH 1975 Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. New York: Wiley and Sons; 134-214.
27. Stoner EJ. 1990 The clinical development of a 5 alpha-reductase inhibitor, finasteride. Steroid Biochem Mol Biol. 37:375-378.
28. Norman RW, Coakes KE, Wright AS, Rittmaster RS. 1993 Androgen metabolism in men receiving finasteride before prostatectomy. J Urol. 150:1736-1739.
29. Hamilton J. 1942 Male-hormone stimulation is a prerequisite and an incitant in common baldness. Am J Anat. 71:451-459.
30. Bingham KD, Shaw DA. 1973 The metabolism of testosterone by human male scalp skin. J Endocrinol. 57:111-121.
31. Imperato-McGinley J, Guerrero L, Gautier T, Paterson RE. 1974 Steroid 5 alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 186:1213-1217.
32. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD 1974 Familial incomplete male pseudohermaphroditism type 2 decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 291:944-949.
33. Parker F. 1974 Skin and hormones. In: Williams, RH, ed. Textbook of Endocrinology. Philadelphia: WB Saunders; 977-993.
34. Ebling FJG, Ebling E, McCafferty V, Skinner J 1974 The responses of the sebaceous glands of the hypophysectomized-castrated male rat to 5α-androstane-3β, 17β-diol. J Invest Dermatol. 60:183-187.
35. Adachi K, Kano M. 1970 Adenyl cyclase in human hair follicles: its inhibition by dihydrotestosterone. Biochem Biophys Res Commun. 41:884-890.
36. Neubauer BL, Farid NA, Gray HR, et al. 1995 LY191704: human type [-selective steroid 5α-reductase inhibitor [trans-8-Chloro-1,4,4a,5,6,10b-hexahydro-4-methylbenzo [f]quinolin-3(2H)-one]. Drugs of the Future 20:144-147.
37. Delos S, Iehle C, Martin P-M, Raynaud J-P. 1994 Inhibition of the "basic" 5α-reductase (type I) detected in DU145 cells and expressed in insect cells. J Steroid Biochem Molec Biol. 48:347-352.
38. Kaefer M, Audia JE, Bruchovsky N, et al., Characterization of type I steroid 5α-reductase in DU145 human prostatic adenocarcinoma cells. J Steroid Biochem Mol Biol., in press.
39. Sutkowski DM, Goode RL, Hsiao EC, McNulty AM, Bruchovsky N, Audia JE, Neubauer BL., Antiproliferative activity of the type I steroid 5α-reductase inhibitor, LY300502 against the LNCaP human prostatic adenocarcinoma cell line. Cancer Res., in press.